Angiotensin II Blockers Market: Competitive Landscape, Pipeline, and Market Analysis 2024

Angiotensin is a peptide hormone that causes vasoconstriction and an increase in blood pressure. It is part of the renin–angiotensin system, which regulates blood pressure. Angiotensin also stimulates the release of aldosterone from the adrenal cortex to promote sodium retention by the kidneys. Angiotensin I is converted to angiotensin II (AII) through the removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung (but also present in endothelial cells, kidney epithelial cells, and the brain). Angiotensin II acts on the central nervous system to increase vasopressin production and also acts on venous and arterial smooth muscle to cause vasoconstriction. Angiotensin II also increases aldosterone secretion; it therefore acts as an endocrine, autocrine/paracrine, and intracrine hormone. The mechanism of action (MOA) of Angiotensin II Blockers is by blocking the action of angiotensin II by preventing angiotensin II from binding to angiotensin II receptors on the muscles surrounding blood vessels.

As a result, blood vessels enlarge (dilate), and blood pressure is reduced. Reduced blood pressure makes it easier for the heart to pump blood and can improve heart failure. Angiotensin II Blockers is used for the treatment of hypertension, acute coronary syndrome, heart diseases, arteriosclerosis, bone diseases, CNS disorders, diabetes mellitus, glaucoma, endocrine diseases, and kidney diseases, to name a few. Increased prevalence of heart diseases and hypertension due to changing lifestyles are the key drivers for the Angiotensin II Blockers market. For instance, According to the Centers For Disease Control and Prevention 2020, an estimated 5.5% of adults reported that they had been diagnosed with heart disease in the US. Launch of newer products by the market players could seek opportunities that influence extensive research and development in Angiotensin II Blockers. For instance, Novartis launched Entresto (Sacubitril And Valsartan) for the treatment of cardiovascular diseases. Moreover, the development of novel molecules by many market players is coming up to overcome challenges in therapy. For instance, Roche’s Vanucizumab (RG7221) for the indication of colorectal cancer is under the various stages of clinical studies.

Key Market Developments:

• In October 2019, Novartis received an FDA grant for an expanded indication for Entresto (Sacubitril And Valsartan) in the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older.
• In February 2021, Novartis received an FDA grant for an expanded indication for the Entresto (Sacubitril And Valsartan) to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure.

Approved Drug Molecules and Brand Names for Angiotensin II Blockers:

• Entresto (Sacubitril And Valsartan)
• Azor (Amlodipine Besylate,Olmesartan Medoxomil)
• Benicar HCT (Olmesartan Medoxomil And Hydrochlorothiazide) And Others

Drugs under the Pipeline for Angiotensin II Blockers:

• Telmunivo (S-Amlidioine / Telmisartan)
• Coaprovel (Irbesartan Hydrochlorothiazide)
• Amlodipine/Ezetimibe/Rosuvastatin/Telmisartan (CKD-348)
• Nesvacumab (REGN910)
• Exone-R (Amlodipine/Rosuvastatin/Valsartan)
• Telmiduo Plus (Amlodipine/Rosuvastatin/Telmisartan)
• Amlodipine/Rosuvastatin/Telmisartan (YH22189)
• Vanucizumab (RG7221)
• ASKG712
• Rosuampin (YHP1701)
• Amlodipine/Atorvastatin/Valsartan (IN-C008)
• Amlodipine/Rosuvastatin/Telmisartan (DW-1501)
• Rosuvastatin/Valsartan
• Valsartan/Amlodipine/Chlorthalidone (AJU-C52L)

Clinical Activity and Developments of Angiotensin II Blockers:

Till July 2023, more than 14 companies having approximately 17 molecules targetting the 47 diseases. For these molecules, more than 85 clinical trials are being conducted and majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,

• In October 2020, Sanofi has completed phase 4, an observational prospective study of Azilsartan Medoxomil/Chlorthalidone Compared With Irbesartan/Hydrochlorothiazide combination therapy in patients with arterial hypertension and obesity in routine clinical practice (PUZZLE).
• In June 2023, Chong Kun Dang has completed a phase I clinical trial to evaluate the tolerability and the pharmacokinetics of CKD-348 with co-administration of CKD-828, D097, and D337 in healthy adult volunteers.